ImmunoReagents and ProteoVec Announce Corporate Partnership and New Product Launch

RALEIGH, N.C. - March 16, 2015 - PRLog -- Leading Life Science Reagent Manufacturer ImmunoReagents joins forces with Bioseparations Technology Innovator ProteoVec to transform antibody purification.  As part of a strategic corporate alliance, the two companies plan to market PV-Pure Ig™ microscale antibody purification kits for use by researchers in the diagnostics, academic, pharmaceutical and life-science fields.

“Our goal is to replace the use of Proteins A and G in antibody purification”, said ProteoVec’s COO/CSO Dr. David Spencer.  “Current technology is too limiting because of low binding densities and inability to purify immune globulins from several species.  PV-Pure Ig uses novel, highly stable molecules to very selectively bind and elute an unprecedented range of antibodies.”

“The research community has been waiting decades for a real innovation in the field of antibody purification,” said ImmunoReagents CEO Dr. Ann Black.  “Working with ProteoVec, ImmunoReagents will, over the next weeks and months launch a series of innovative antibody purification kits with substantial advantages over current technologies.”

About ImmunoReagents, Inc.

ImmunoReagents is a leading global manufacturer of quality antibodies and reagents used in research and in vitro diagnostics. Product offerings include a wide range of immunochemistry reagents such as purified immunoglobulins, primary antibodies and secondary antibodies covering a broad spectrum of immunoglobulin from various species. ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located in Raleigh, North Carolina.

For more information, please see http://www.immunoreagents.com

About ProteoVec, Inc.

With operations in Louisiana and North Carolina, PV has developed the LigaTrap technology:  a platform for generating highly stable low molecular weight affinity ligands attached to resins or membranes.  The first product from this technology is PV-Pure Ig, designed for ultra-high density capture of an unusually broad range of recombinant monoclonal and human/animal source polyclonal immune globulins.  ProteoVec also offers preclinical protein expression and manufacturing services in state-of-the-art disposable systems for rapid development needs.

For more information please visit:   http://www.proteovec.com.